Flanders Future Techfund leads €10 million seed round in Spica Therapeutics

Cresco acted as counsel to Flanders Future Techfund in connection with its investment in the €10 million seed financing round of Spica Therapeutics, a Belgian-Danish biotech company pioneering macrophage-targeted therapies for cancer, fibroinflammatory and autoimmunediseases.

Spica Therapeutics was founded in 2024 following research into macrophage biology conducted in Denmark, and operates from its headquarters in Belgium. The company’s proprietary platform leverages functional macrophage fingerprinting to identify and selectively target disease-relevant macrophage subsets, aiming to develop first-in-class therapies.

The financing round, led by Flanders Future Techfund and Bioqube Ventures, will support Spica’s preclinical development of its lead programs and further advancement of its platform technology.

The Cresco deal team consisted of David Dessers, Rutger Duden and Lotte Wuyts.

For any further information or questions, please contact David Dessers.

For more information, please visit De Tijd.

Team

David Dessers
Founding Partner
Rutger Duden
Associate
Lotte Wuyts
Associate

Expertises

corporate venturing